Most people have heard of fentanyl. Nitazenes are what comes after. A class of synthetic opioids developed in the late 1950s and never approved for medical use, nitazenes began appearing in the illicit drug supply in 2019 and have been proliferating since. Some analogs are estimated to be 500 to 1,000 times more potent than morphine, meaning even trace quantities can cause fatal respiratory arrest. They are structurally unrelated to fentanyl, which means they evade many standard drug tests and may respond differently to naloxone. For anyone affected by the opioid crisis, whether personally or as a family member, understanding what nitazenes are is now part of staying safe.
Nitazenes are a class of 2-benzylbenzimidazole opioids, structurally distinct from morphine-derived opioids and from fentanyl. They were synthesized in the 1950s as potential analgesics but were never developed for clinical use because early research showed an unfavorable ratio between therapeutic effect and toxicity. For decades they existed primarily as research compounds used to study opioid receptor pharmacology, known mainly to specialists in that field.
The first nitazene to appear in the recreational drug market was isotonitazene, detected in Europe, Canada, and the United States in 2019. It circulated under the street names Iso and Tony. After isotonitazene was internationally scheduled in 2021, manufacturers shifted to other analogs. Metonitazene, etonitazene, and protonitazene followed. Because the nitazene chemical family contains many possible variations, illicit chemists have continued producing new analogs as existing ones are scheduled, creating a rolling succession that regulators have struggled to keep pace with. The NIDA opioid overdose crisis overview tracks the evolution of novel synthetic opioids entering the supply.
Potency comparisons between opioids are measured relative to morphine as a baseline. Fentanyl, which most people now understand to be extraordinarily dangerous, registers at approximately 50 to 100 times the potency of morphine. The most potent nitazene analogs are estimated at 500 to 1,000 times the potency of morphine, placing them in a category well above fentanyl.
What this means practically is that a quantity of nitazene invisible to the naked eye can cause fatal respiratory depression. Someone who has been using fentanyl-laced drugs and has built some tolerance to fentanyl has no meaningful tolerance to nitazenes. The drugs are different enough at the receptor level that prior opioid exposure does not provide reliable protection.
Nitazenes also present a specific challenge with naloxone reversal. Research published in peer-reviewed pharmacology literature has found that certain nitazene analogs dissociate from the mu-opioid receptor more slowly than fentanyl, meaning standard naloxone doses may be insufficient to fully reverse an overdose. Multiple doses are often required. The CDC overdose prevention resources include updated guidance on naloxone dosing and overdose response for high-potency opioids.
This is the aspect of nitazenes that public health researchers find most alarming: most people who encounter nitazenes do not know they are doing so. The compounds appear as adulterants in substances sold as heroin, fentanyl, or counterfeit pills. A person who believes they are using a familiar opioid product may actually be consuming a nitazene analog they have no tolerance for, at a potency level orders of magnitude higher than expected.
The ease and low cost of synthesizing nitazenes drives their presence in the supply. Because the nitazene family is structurally distinct from the opioids typically detected on standard immunoassay drug panels, they are largely invisible to routine toxicology screening. A person can overdose on a nitazene analog and test negative for all standard opioids on a basic screen. Specialized confirmatory testing using liquid chromatography-mass spectrometry is required for detection.
A nitazene overdose produces the same clinical signs as any opioid overdose, but onset may be faster and severity more extreme given the potency involved:
If any of these signs are present, call 911 immediately. Administer naloxone if available, knowing that multiple doses may be needed. The standard guidance of two sprays of 4mg intranasal naloxone followed by a third if the person does not respond within two to three minutes applies, but with nitazenes additional doses may still be necessary even after that. Do not leave the person alone. Do not assume the first dose resolved the overdose.
Opioid use disorder involving nitazenes is treated through the same evidence-based framework as other opioid use disorders, because nitazenes act on the same mu-opioid receptors. Medications for opioid use disorder, specifically buprenorphine and methadone, are the first-line treatments supported by the American Society of Addiction Medicine and SAMHSA.
One clinical consideration specific to nitazene use involves the diagnostic picture. Because nitazenes do not show on standard drug tests, a person seeking treatment for opioid use disorder may not receive a complete clinical picture at intake if only standard screening is used. Disclosing the full range of substances used, or requesting extended toxicology, helps clinicians design the most appropriate treatment plan.
The broader treatment framework remains the same: medically managed withdrawal, medication maintenance with buprenorphine or methadone where appropriate, behavioral therapy addressing the psychological dimensions of addiction, and an aftercare plan that reduces relapse risk. For people who have survived a nitazene overdose, naloxone access and training for family members is a critical safety component during early recovery. SAMHSA's treatment locator connects people with opioid use disorder programs by location at no cost.
For context on the risk factors that make some people more vulnerable to opioid use disorder, our piece on who is more likely to use drugs covers the genetic, neurological, and environmental factors clinicians and families should understand.
The most widely identified nitazene in the illicit supply was isotonitazene, sold under the street names Iso and Tony. As regulation has driven a shift to other analogs, street names have become less consistent. Most people who have encountered nitazenes did not know the substance by any name because it was sold as something else entirely, typically heroin or fentanyl.
Nitazene detections have been reported across multiple states, with concentrations in areas where the illicit opioid supply is most active. CDC and forensic surveillance data document the compounds across both coasts and into the Midwest. Given that nitazenes are largely invisible on standard drug tests, reported detections likely undercount actual prevalence.
Yes. Naloxone works on nitazene overdose because nitazenes act on the same mu-opioid receptors that naloxone blocks. The critical difference is that some nitazene analogs may require higher doses of naloxone than a typical fentanyl overdose would. Multiple doses administered at two to three minute intervals are often needed. Emergency care is required regardless of initial naloxone response.
Yes. Physical dependence develops with repeated opioid exposure regardless of which specific opioid is involved. Someone who has been using what they believed was heroin or fentanyl and who experiences withdrawal symptoms when they stop may have been using a nitazene-adulterated supply without any awareness of it. Treatment for opioid use disorder addresses the dependence and behavioral dimensions regardless of which opioid was involved.
The opioid supply has become unpredictable in ways that increase risk for anyone using opioids outside a medical context. Nitazenes are part of that unpredictability. Whether someone is seeking help for themselves or trying to help a family member, the treatment system does not require knowing every substance involved. It requires access to competent clinical care.
Our treatment finder connects people with accredited programs equipped to treat opioid use disorder at any stage. If the situation is urgent, the SAMHSA National Helpline (1-800-662-4357) is available 24 hours a day, free and confidential, for individuals and families.
